33833333|t|Basmisanil, a highly selective GABAA-alpha5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.
33833333|a|GABAA-alpha5 subunit-containing receptors have been shown to play a key modulatory role in cognition and represent a promising drug target for cognitive dysfunction, as well as other disorders. Here we report on the preclinical and early clinical profile of a novel GABAA-alpha5 selective negative allosteric modulator (NAM), basmisanil, which progressed into Phase II trials for intellectual disability in Down syndrome and cognitive impairment associated with schizophrenia. Preclinical pharmacology studies showed that basmisanil is the most selective GABAA-alpha5 receptor NAM described so far. Basmisanil bound to recombinant human GABAA-alpha5 receptors with 5 nM affinity and more than 90-fold selectivity versus alpha1, alpha2, and alpha3 subunit-containing receptors. Moreover, basmisanil inhibited GABA-induced currents at GABAA-alpha5 yet had little or no effect at the other receptor subtypes. An in vivo occupancy study in rats showed dose-dependent target engagement and was utilized to establish the plasma exposure to receptor occupancy relationship. At estimated receptor occupancies between 30 and 65% basmisanil attenuated diazepam-induced spatial learning impairment in rats (Morris water maze), improved executive function in non-human primates (object retrieval), without showing anxiogenic or proconvulsant effects in rats. During the Phase I open-label studies, basmisanil showed good safety and tolerability in healthy volunteers at maximum GABAA-alpha5 receptor occupancy as confirmed by PET analysis with the tracer [11C]-Ro 15-4513. An exploratory EEG study provided evidence for functional activity of basmisanil in human brain. Therefore, these preclinical and early clinical studies show that basmisanil has an ideal profile to investigate potential clinical benefits of GABAA-alpha5 receptor negative modulation.
33833333	0	10	Basmisanil	Chemical	MESH:C000720034
33833333	44	52	negative	Chemical	-
33833333	301	322	cognitive dysfunction	Disease	MESH:D003072
33833333	447	455	negative	Chemical	-
33833333	484	494	basmisanil	Chemical	MESH:C000720034
33833333	538	561	intellectual disability	Disease	MESH:D008607
33833333	565	578	Down syndrome	Disease	MESH:D004314
33833333	583	603	cognitive impairment	Disease	MESH:D003072
33833333	620	633	schizophrenia	Disease	MESH:D012559
33833333	680	690	basmisanil	Chemical	MESH:C000720034
33833333	757	767	Basmisanil	Chemical	MESH:C000720034
33833333	789	794	human	Species	9606
33833333	945	955	basmisanil	Chemical	MESH:C000720034
33833333	966	970	GABA	Chemical	MESH:D005680
33833333	1094	1098	rats	Species	10116
33833333	1278	1288	basmisanil	Chemical	MESH:C000720034
33833333	1300	1308	diazepam	Chemical	MESH:D003975
33833333	1325	1344	learning impairment	Disease	MESH:D007859
33833333	1348	1352	rats	Species	10116
33833333	1409	1414	human	Species	9606
33833333	1460	1470	anxiogenic	Disease	
33833333	1499	1503	rats	Species	10116
33833333	1544	1554	basmisanil	Chemical	MESH:C000720034
33833333	1702	1705	11C	Chemical	MESH:C000615233
33833333	1707	1717	Ro 15-4513	Chemical	MESH:C042957
33833333	1789	1799	basmisanil	Chemical	MESH:C000720034
33833333	1803	1808	human	Species	9606
33833333	1882	1892	basmisanil	Chemical	MESH:C000720034
33833333	1982	1990	negative	Chemical	-
33833333	Negative_Correlation	MESH:C000720034	MESH:D003072
33833333	Positive_Correlation	MESH:D003975	MESH:D007859
33833333	Negative_Correlation	MESH:C000720034	MESH:D003975
33833333	Negative_Correlation	MESH:C000720034	MESH:D007859
33833333	Negative_Correlation	MESH:C000720034	MESH:D004314
33833333	Negative_Correlation	MESH:C000720034	MESH:D012559
33833333	Negative_Correlation	MESH:C000720034	MESH:D008607

